Back to results
US 2019/0293653 A1Published application
Urine metabolite marker for childhood cancer
AssigneesHitachi, Ltd., National University Corporation Nagoya University
InventorsHiroo Uchida, Akinari Hinoki, Minoru Sakairi, Mayumi Abe
Life of this patent
Estimating the term…
Abstract
Provided is a method, a device and a kit for detecting childhood cancer, predicting the risk of childhood cancer, determining the stage of the childhood cancer, determining the prognosis of the childhood cancer, and/or monitoring the effect of a treatment for the childhood cancer in a subject by measuring ae urinary metabolite of the subject.
Claims13
A method for evaluating a childhood cancer, comprising:
- a step of measuring a urinary metabolite in a urine sample derived from a subject;
- and
- a step of evaluating a childhood cancer in the subject on the basis of the result of the measurement,
- wherein the urinary metabolite comprises at least one metabolite selected from the group consisting of:
- (i) at least one metabolite selected from the group consisting of 3-methoxytyramine sulfate, vanillactate, homovanillate, vanillylmandelate, 3,4-dihydroxyphenylacetate, phenol glucuronide, 3,4-dihydroxyphenylacetate sulfate, 3-methoxytyrosine, 3-methoxytyramine, 3-methoxy-4-hydroxyphenylglycol, and dopamine;
- (ii) at least one metabolite selected from the group consisting of N-acetylcysteine, cystathionine, and S-adenosylhomocysteine;
- (iii) at least one metabolite selected from the group consisting of cortisol 21-glucuronide and cortisol;
- and
- (iv) a metabolite which is xanthopterin,
- provided that if the urinary metabolite to be evaluated is only one, it is not homovanillate or vanillylmandelate.
7 more elements
A device for evaluating a childhood cancer comprising:
- a measurement unit which is configured to measure a urinary metabolite in a urine sample;
- a comparison unit which is configured to compare a measurement value of the urinary metabolite measured by the measurement unit with a reference value or a previous measurement value;
- and
- a determination unit which is configured to evaluate the childhood cancer from a comparison result obtained by the comparison unit,
- wherein the urinary metabolite comprises at least one metabolite selected from the group consisting of:
- (i) at least one metabolite selected from the group consisting of 3-methoxytyramine sulfate, vanillactate, homovanillate, vanillylmandelate, 3,4-dihydroxyphenylacetate, phenol glucuronide, 3,4-dihydroxyphenylacetate sulfate, 3-methoxytyrosine, 3-methoxytyramine, 3-methoxy-4-hydroxyphenylglycol, and dopamine;
- (ii) at least one metabolite selected from the group consisting of N-acetylcysteine, cystathionine, and S-adenosylhomocysteine;
- (iii) at least one metabolite selected from the group consisting of cortisol 21-glucuronide and cortisol;
- and
- (iv) a metabolite which is xanthopterin,
- provided that if the urinary metabolite to be evaluated is only one, it is not homovanillate or vanillylmandelate.
8 more elements
A method for evaluating the efficacy of a treatment for a childhood cancer, comprising:
- a step of measuring a urinary metabolite in a urine sample from an animal having a childhood cancer which was treated with a therapeutic drug or a therapeutic method to be tested;
- and
- a step of evaluating the efficacy of the therapeutic drug or the therapeutic method to be tested for the childhood cancer on the basis of the result of the measurement,
- wherein the urinary metabolite comprises at least one metabolite selected from the group consisting of:
- (i) at least one metabolite selected from the group consisting of 3-methoxytyramine sulfate, vanillactate, homovanillate, vanillylmandelate, 3,4-dihydroxyphenylacetate, phenol glucuronide, 3,4-dihydroxyphenylacetate sulfate, 3-methoxytyrosine, 3-methoxytyramine, 3-methoxy-4-hydroxyphenylglycol, and dopamine;
- (ii) at least one metabolite selected from the group consisting of N-acetylcysteine, cystathionine, and S-adenosylhomocysteine;
- (iii) at least one metabolite selected from the group consisting of cortisol 21-glucuronide and cortisol;
- and
- (iv) a metabolite which is xanthopterin,
- provided that if the urinary metabolite to be evaluated is only one, it is not homovanillate or vanillylmandelate.
7 more elements
Dependencies are inferred from the claim text.